ClinicalTrials.gg
SuspendedNCT07181382SERANATAUpdated Mar 19, 2026

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Phase 3 interventional study of Placebo and Seralutinib in Pulmonary Hypertension Associated With Interstitial Lung Disease, sponsored by GB002, Inc.. Suspended at 4 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by GB002, Inc. · Phase 3, Interventional, and Treatment

Why this study was suspended
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 397 studies in Hypertension, Pulmonary with a site in United States — 73 open to participants now, 87 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.

Planned enrollment
11th of 286
480 · median 30
Started
2026
with 23 others
Phase 3
65 of 397
6 open now
Registered
372nd of 397
by date

Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 11th largest by planned enrollment of the 286 interventional ones that give a count, is one of 24 that started in 2026, is one of 65 in phase 3, and was the 372nd registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

73 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 397 studies in Hypertension, Pulmonary with a site in United States, or all of them as a file.
02

Study summary

This Phase 3 study is designed as a 24-week randomized, double-blind, placebo-controlled period (PCP) followed by a 144-week long-term extension (LTE) period. The primary objective of the PCP is to evaluate the effect of seralutinib on improving exercise capacity in subjects with World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease. The primary objective of the LTE is to evaluate the long-term safety and tolerability of seralutinib.

03

Conditions studied

  • Pulmonary Hypertension Associated With Interstitial Lung Disease

Keywords

  • seralutinib
  • GB002
  • SERANATA
  • Pulmonary hypertension
  • Interstitial lung disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult subjects aged 18 years to 80 years, inclusive, at the time of voluntarily signing the form, prior to initiation of any study-specific activities/procedures.
  2. (BMI) ≥ 15 kg/m2 and ≤ 40 kg/m2.
  3. A diagnosis of WHO Group 3 pulmonary hypertension (PH) associated with interstitial lung disease.
  4. Right heart catheterization at Screening meeting the following criteria:

    1. Pulmonary vascular resistance (PVR) ≥ 4 Woods Units, AND
    2. Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) ≤ 15 mm Hg, AND
    3. Mean pulmonary arterial pressure (mPAP) ≥ 25 mm Hg. Historic RHC up to 12 weeks prior to Screening may be acceptable for eligibility.
  5. Forced vital capacity (FVC) ≥ 45% predicted at Screening.
  6. Screening 6MWD of ≥ 100 m and ≤ 475 m.
  7. Subjects receiving permitted chronic medication for underlying fibrotic ILD must be receiving background therapy from at least 16 weeks prior to Screening.
  8. Subjects receiving SARD medication must be receiving background therapy from at least 16 weeks prior to Screening.
  9. Subjects on supportive medications (eg, diuretics) must be on an optimized dose for ≥ 30 days prior to and throughout Screening.
  10. In the opinion of the Investigator, the subject has no other medical conditions that impair the proper use of the inhaler.
  11. Women of (WOCBP) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on PCP Day 1 before first administration of IP.
  12. WOCBP who are not abstinent and intend to be sexually active with a non-sterilized male partner must be willing to use a highly effective method of from consent through 30 days following the last administration of IP.
  13. Women of nonchildbearing potential (WONCBP), classified by 1 of the following:

    1. Surgical sterilization
    2. Evidence of status.
  14. Male subjects: Non-sterilized male subjects who are not abstinent and intend to be sexually active with a female partner of childbearing potential must use a male condom from consent through 90 days after the last dose of IP.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of pulmonary arterial hypertension (PAH) or PH other than WHO Group 3.
  2. PH associated with sarcoidosis, combined pulmonary fibrosis and emphysema, , or progressive massive fibrosis.
  3. (HIV).
  4. Uncontrolled atrial fibrillation or paroxysmal atrial fibrillation.
  5. History of a potentially life-threatening cardiac arrhythmia with an ongoing risk.
  6. Uncontrolled systemic hypertension
  7. Subjects receiving > 10 L/min of oxygen supplementation via nasal cannula at rest or > 15 L/min during six-minute walk tests conducted during Screening.
  8. Acute pulmonary embolism within 12 weeks prior to and throughout Screening.
  9. Untreated moderate or severe obstructive sleep apnea.
  10. history of liver disease (ie, Class A - C, viral hepatitis, liver cirrhosis, hepatobiliary disorders, etc).
  11. History of within 5 years prior to Screening, with the exception of localized and adequately treated non- basal and squamous cell carcinoma of the skin and in-situ carcinoma of the cervix.
  12. Uncontrolled bacterial, viral, or fungal infections which require ongoing systemic therapy.
  13. Severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or IP administration, or (ANC) \< 1 x 109/L.
  14. Pregnant or nursing or intends to become pregnant during the duration of the study.
  15. Major surgical procedures planned to occur during trial period.
  16. Any other medical condition or laboratory abnormality that, in the opinion of the Investigator, would prohibit the subject from participating in the study, eg, severe concomitant illness limiting (\< 24 weeks).
  17. Body weight \< 40 kg at Screening.
  18. Estimated (eGFR) \< 45 mL/min/1.73 m2
  19. Evidence of active or , or active tuberculosis (TB) infections at Screening.
  20. Subjects receiving both nintedanib and pirfenidone.
  21. Initiation of an exercise program for cardiopulmonary rehabilitation within 12 weeks prior to and throughout Screening or planned during their time on the PCP.
  22. Prior participation in seralutinib studies and/or prior treatment with seralutinib.
  23. Currently participating in or has participated in a study of an agent or has used an investigational device for the treatment of PH-ILD within 12 weeks or 5 half-lives of the investigational agent, whichever is longer, prior to Screening.
  24. Current use or within 24 weeks prior to Randomization of inhaled tobacco- or nicotine-containing products (including e-vapor products) and/or inhaled marijuana.
  25. Current alcohol use disorder based on the opinion of the Investigator, and/or a positive test for drugs of abuse at Screening.
  26. Subjects with a history of severe milk protein allergy.
  27. corrected for heart rate using Fridericia's formula (QTcF) of > 500 msec.
  28. In the opinion of the Investigator, the subject has any condition that would interfere with the interpretation of study assessments or has any disease or condition that would likely be the primary limit to ambulation (as opposed to PH).

NOTE: Additional inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
480 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo inhaled orally twice daily (BID) for 24 weeks in PCP. Subjects randomized to the placebo treatment group in the PCP will receive seralutinib in LTE.

    Drug: Placebo · Drug: Seralutinib · Device: Generic Dry Powder Inhaler

  • Experimental
    Seralutinib 90 mg

    Seralutinib inhaled orally BID for 24 weeks in PCP. Seralutinib inhaled orally BID up to 144 weeks in LTE.

    Drug: Seralutinib · Device: Generic Dry Powder Inhaler

  • Experimental
    Seralutinib 120 mg

    Seralutinib inhaled orally BID for 24 weeks in PCP. Seralutinib inhaled orally BID up to 144 weeks in LTE.

    Drug: Seralutinib · Device: Generic Dry Powder Inhaler

Interventions

  • DrugPlacebo

    Matching capsule containing placebo

  • Capsule containing seralutinib

  • DeviceGeneric Dry Powder Inhaler

    Generic dry powder inhaler for seralutinib or placebo delivery

06

What researchers measure

Primary outcomes

  1. Change in distance achieved on the six-minute walk test (6MWT), from baseline to PCP Week 24

    Time frame: Baseline to PCP Week 24

  2. Incidence of treatment-emergent adverse events

    Time frame: From first dose of LTE study treatment through LTE Week 148

Secondary outcomes

  1. Time to first event of Adjudication Committee (AC)-confirmed clinical worsening from first dose of investigational product (IP) through PCP Week 24

    Event is defined as: * Death (all causes) * Hospitalization for ≥ 24 hours due to a worsening cardiopulmonary indication * ≥ 15% 6MWD decline from baseline, directly related to PH-ILD assessed by two 6MWTs at least 4 hours apart and no more than 1 week apart

    Time frame: Baseline to PCP Week 24

  2. Change in N-terminal pro b-type natriuretic peptide (NT-proBNP) from baseline to PCP Week 24

    Time frame: Baseline to PCP Week 24

  3. Change in absolute forced vital capacity (FVC) from baseline to PCP Week 24

    Time frame: Baseline to PCP Week 24

  4. Proportion of subjects meeting each AC-confirmed component of clinical worsening by PCP Week 24

    Components of clinical worsening are defined for the first secondary outcome measure above.

    Time frame: Baseline to PCP Week 24

  5. Change in Euro-QoL - 5 Dimensions - 5 Levels (EQ-5D-5L) from baseline to PCP Week 24

    The EQ-5D-5L is a patient questionnaire that includes two components. The first is the EQ-5D-5L descriptive system, which profiles a subject's current health state across 5 dimensions (Mobility, Self-Care, Usual Activities, Pain/Discomfort, Anxiety/Depression). Each dimension is comprised of a single question with 5 possible responses that are scored 1-5, corresponding to no problems, slight problems, moderate problems, severe problems, and unable to/extreme problems, respectively. Higher scores for a dimension mean a worse outcome. The second is a visual analogue scale (EQ VAS), which asks a subject to assess their overall health. The EQ VAS has a range of 0-100, with a higher score representing a better outcome.

    Time frame: Baseline to PCP Week 24

  6. Change in Living with Pulmonary Fibrosis (L-PF) from baseline to PCP Week 24

    Time frame: Baseline to PCP Week 24

  7. Changes in distance achieved on the 6MWT

    Time frame: LTE Week 12 to LTE Week 148

  8. Changes in NT-proBNP

    Time frame: LTE Week 4 to LTE Week 148

  9. Changes in absolute forced vital capacity (FVC)

    Time frame: LTE Week 12 to LTE Week 148

07

Study locations

4 sites
  • Valley Advanced Lung Diseases Institute
    Fresno, California 93720, United States
  • University of New Mexico Health Sciences Center
    Albuquerque, New Mexico 87131, United States
  • Pulmonary Associates of Richmond, Inc.
    Richmond, Virginia 23230, United States
  • Hillel Yaffe Medical Center
    Hadera, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Dec 2028, 34 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2025
First posted
Sep 18, 2025
StartEst.
Feb 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07181382
Lead sponsor
GB002, Inc.
Responsible party
Sponsor
First posted
Sep 18, 2025
Start date
Feb 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Mar 19, 2026

Study contacts

Richard Aranda, MD
study director · Gossamer Bio USA, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seralutinib

Start the discussion